Duane Boise stated "At the center of the MMJ cannabis pharmaceutical litigation sits DEA Thomas Prevoznik, an unearthed official with no medical or scientific expertise, who wields unchecked power to deny therapies under the guise of public safety."
MMJ BioPharma Cultivation: A Case Study in DEA Sabotage
WASHINGTON, D.C. / ACCESS Newswire / May 12, 2025 / While the FDA advances groundbreaking clinical trials for cannabinoid-based treatments targeting Huntington's Disease, Multiple Sclerosis, and other incurable conditions, the Drug Enforcement Administration (DEA) has weaponized its authority to sabotage progress. In an era demanding scientific collaboration, the DEA operates as a rogue entity-prioritizing bureaucratic power over patient lives.
MMJ BioPharma Cultivation, the sole company supporting two FDA-authorized Investigational New Drug (IND) programs, has faced relentless DEA obstruction. Their pharmaceutical-grade cannabinoid therapies, backed by rigorous clinical protocols, international distribution plans, and GMP manufacturing-are stalled by the DEA's refusal to approve its cultivation license. MMJ BioPharma Cultivation applied in 2018 and has meet all the federal requirements. Even despite submitting corrective action plans, the DEA has dismissed appeals through closed door rulings, leaving patients without lifelines.
A System Designed to Fail
The Supreme Court's Axon ruling made it clear: administrative agencies do not get to serve as judge, jury, and executioner. Yet the DEA's unconstitutional use of administrative law judges-accountable to no one, removable by no one-is still the gatekeeper for scientific research in America. Worse, Thomas Prevoznik and others continue to impose arbitrary roadblocks under the guise of "public safety," despite overwhelming evidence that these therapies could transform the lives of patients suffering from chronic, incurable diseases.
Congress Must Act: Patients Are Running Out of Time
Many Americans suffer from Huntington's and Multiple Sclerosis. Thousands more battle chronic pain, epilepsy, and PTSD-conditions with cannabinoid therapies trapped in DEA purgatory. Every delayed approval is a painful sentence for those without treatment relief options.
The Path Forward
Terminate Thomas Prevoznik's Authority: Remove officials who weaponize bureaucracy against science.
Overhaul the DEA's Research Framework: Align agency protocols with 21st-century medical standards.
Enforce Transparency: End closed-door rulings and require public justification for denials.
The Stakes Could Not Be Higher
How many patients must continue to live in agony before Congress reins in this rogue agency? The DEA's draconian grip on medical cannabis research is unconstitutional, immoral, and indefensible. Patients deserve therapies vetted by science-not stonewalled by DEA stigma.
Fire Thomas Prevoznik. Reform DEA Now. End the DEA's Medical Blockade.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
mhisey@mmjih.com
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
